Primary Safety Endpoints: • Incidence of treatment (dose)-related serious adverse events. • Incidence of all adverse events related or unrelated to the study treatment. Primary Efficacy Endpoints: • Proportion of patients with respiratory rate < 23/min for at least 24 hours, on Day 7. • Proportion of patients with SpO2 saturation >94%, on room air for at least 24 hours, on Day 7. • Proportion of patients with a decrease by 50% in either CRP/LDH/Fibrinogen/Ferritin/D-dimers from baseline to Day 7.

Primary Safety Endpoints: • Incidence of treatment (dose)-related serious adverse events. • Incidence of all adverse events related or unrelated to the study treatment. Primary Efficacy Endpoints: • Proportion of patients with respiratory rate < 23/min for at least 24 hours, on Day 7. • Proportion of patients with SpO2 saturation >94%, on room air for at least 24 hours, on Day 7. • Proportion of patients with a decrease by 50% in either CRP/LDH/Fibrinogen/Ferritin/D-dimers from baseline to Day 7.